Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omegaven for intestinal failure-associated liver disease in pediatric patients
jRCTs031240436Active, not recruiting
- Sponsor
- National Center for Child Health and Development
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of eicosapentaenoic acid + docosahexaenoic acid in intestinal failure-associated liver disease (IFALD), sponsored by National Center for Child Health and Development. Primary endpoint: Primary efficacy endpoint. Started Oct 2024; status: active, not recruiting.
02
Drugs
eicosapentaenoic acid + docosahexaenoic acid
03
Conditions
intestinal failure-associated liver disease (IFALD)
Beyond the preview
Go deeper on jRCTs031240436.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031240436.